Bovine pericardial valve market seen reaching $2.53 billion by 2030

The bovine pericardial valve market is projected to grow from $1.72 billion in 2026 to $2.53 billion by 2030, according to The Business Research Company. Demand is being driven by rising cardiovascular disease, more minimally invasive procedures and broader use of biologic heart valves.

Why it matters: - The market is tied to a growing need for heart valve replacement solutions as cardiovascular disease rates rise and populations age. - Faster adoption of minimally invasive and transcatheter procedures is expanding the use case for bovine pericardial valves. - The shift toward biologic valves with less need for anticoagulation could influence treatment choices and surgical planning.

What happened: - The Business Research Company released its Bovine Pericardial Valve Global Market Report 2026. - The report projects the market will rise from $1.57 billion in 2025 to $1.72 billion in 2026. - The report forecasts the market will reach $2.53 billion by 2030. - The forecast implies a 9.9% CAGR from 2025 to 2026 and a 10.1% CAGR through 2030. - The report was dated June 29, 2026, in London.

The details: - Bovine pericardial valves are bioprosthetic heart valves made from cow pericardial tissue. - Surgeons use the valves to replace damaged or diseased native heart valves during cardiac surgery. - The valves are designed for biocompatibility, strong blood flow dynamics and durability. - The valves are engineered to reduce calcification and structural deterioration. - Growth in the market has been supported by rising cases of valvular heart disease in aging patients. - Wider use of open-heart surgical valve replacements has also supported recent growth. - Advances in cardiac surgery techniques and perioperative care have helped market expansion. - Healthcare facilities are offering a broader range of bioprosthetic valve options. - Awareness of cardiovascular treatment options is increasing. - The report identifies rising demand for minimally invasive and transcatheter procedures as a major future driver. - The report also points to progress in tissue engineering and biomaterial technology. - Improvements in healthcare infrastructure and cardiac care access in emerging economies are expected to add demand. - The report says the market is moving toward advanced bioprosthetic materials with better durability. - The report also flags greater focus on anti-calcification treatments, broader transcatheter heart valve implantation and a clinical preference for long-lasting biologic valves over mechanical alternatives. - The report says North America held the largest market share in 2025. - The Asia-Pacific region is expected to post the fastest growth during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America and the Middle East and Africa. - A free sample is available here. - The full report is available here.

Between the lines: - The forecast suggests demand is shifting from traditional valve surgery toward less invasive techniques and longer-lasting tissue-based products. - The biggest growth opportunities appear to be in markets with expanding cardiac care access and aging populations. - The report’s emphasis on biomaterials and anti-calcification technology suggests product differentiation will matter more as the market matures.

What's next: - The market’s next phase will likely be shaped by transcatheter adoption, biomaterial improvements and broader access to cardiac procedures. - Emerging economies could become more important growth markets if healthcare infrastructure continues to improve. - Manufacturers focused on durability and minimally invasive compatibility may be best positioned for the forecast period.

The bottom line: - Bovine pericardial valves are moving from a niche surgical option to a growth market anchored by aging patients, rising cardiovascular disease and less invasive heart procedures.